| 1.99 Data as of May 17 |  +0.02 / +1.02%Today’s Change | 1.71 Today|||52-Week Range 6.24 | +3.65% Year-to-Date |
| ASCO '13 Preview: Oncothyreon's Failed Lung Cancer Vaccine May 15 / TheStreet.com |
| Previous close | 1.97 |
| Today’s open | 2.00 |
| Day’s range | 1.97 - 2.09 |
| Volume | 4,975,374 |
| Average volume (3 months) | 827,381 |
| Market cap | $113.9M |
| Dividend yield | -- |
| Earnings growth (last year) | +94.64% |
| Earnings growth (this year) | -856.21% |
| Earnings growth (next 5 years) | +0.20% |
| Revenue growth (last year) | -100.00% |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 1.38 |
| Today’s change | Today’s % change | |
|---|---|---|
| ENZEnzo Biochem Inc | +0.03 | +1.33% |
| BSTCBiospecifics Technol... | +0.17 | +1.08% |
| IMUCImmunoCellular Thera... | -0.01 | -0.39% |
| CDXSCodexis Inc | +0.03 | +1.26% |
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -$0.14 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$3.4M |
| Net profit margin | -- |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Robert L. Kirkman, MD |
Chief Operating Officer Gary Christianson |
Corporate headquarters Seattle, Washington |
.
